病毒学报

[1] Warner BM, Sloan A, Deschambault Y, et al.Differential pathogenesis between Andes virus strains CHI-7913 and Chile-9717869in Syrian Hamsters[J]. J Virol, 2021, 95(10):e00108-21. DOI:10. 1128/JVI. 00108-21.

[2] Alonso DO, Kehl SD, Coelho RM, et al.Orthohantavirus diversity in Central-East Argentina:Insights from complete genomic sequencing on phylogenetics, Geographic patterns and transmission scenarios[J]. PLoS Negl Trop Dis, 2024, 18(10):e0012465. DOI:10. 1371/journal. pntd. 0012465.

[3] Chen RX, Gong HY, Wang X, et al. Zoonotic Hantaviridae with global public health significance[J].Viruses, 2023, 15(8):1705. DOI:10. 3390/v15081705.

[4] Safronetz D, Zivcec M, Lacasse R, et al. Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus[J]. PLoS Pathog, 2011, 7(12):e1002426. DOI:10. 1371/journal. ppat. 1002426.

[5]尚翠，杨丽芬，杜珊珊，等. 2018—2019年云南省部分地区鼠类携带汉坦病毒基因型别分析[J].病毒学报，2022, 38(1):149-155. DOI:10. 13242/j. cnki.bingduxuebao. 004076.

[6] Vial PA, Ferrés M, Vial C, et al. Hantavirus in humans:a review of clinical aspects and management[J]. Lancet Infect Dis, 2023, 23(9):e371-e382. DOI:10. 1016/S1473-3099(23)00128-7.

[7] Wang Z, Mir MA. Andes virus nucleocapsid protein interrupts protein kinase R dimerization to counteract host interference in viral protein synthesis[J]. J Virol,2015, 89(3):1628-1639. DOI:10. 1128/JVI. 02347-14.

[8] Simons MJ, Gorbunova EE, Mackow ER. Unique interferon pathway regulation by the Andes Virus nucleocapsid protein is conferred by phosphorylation of serine 386[J]. J Virol, 2019, 93(10):e00338-19.DOI:10. 1128/JVI. 00338-19.

[9] Tischler ND, Fernández J, Müller I, et al. Complete sequence of the genome of the human isolate of Andes virus CHI-7913:comparative sequence and protein structure analysis[J]. Biol Res, 2003, 36(2):201-210. DOI:10. 4067/s0716-97602003000200010.

[10]Vera-Otarola J, Solis L, Lowy F, et al. The Andes Orthohantavirus NSs protein antagonizes the type I interferon response by inhibiting MAVS signaling[J]. J Virol, 2020, 94(13):e00454-20. DOI:10. 1128/JVI. 00454-20.

[11]Kuzmin IV, Soto Acosta R, Pruitt L, et al.Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine[J]. Nat Commun, 2024, 15:6421. DOI:10. 1038/s41467-024-50774-3.

[12]Beltrán-Ortiz CE, Starck-Mendez MF, Fernández Y,et al. Expression and purification of the surface proteins from Andes virus[J]. Protein Expr Purif, 2017, 139:63-70. DOI:10. 1016/j. pep. 2015. 09. 013.

[13]Mittler E, Serris A, Esterman ES, et al. Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody[J]. Sci Transl Med, 2023, 15(700):eadg1855. DOI:10. 1126/scitranslmed.adg1855.

[14]Slough MM, Li R, Herbert AS, et al. Two point mutations in protocadherin-1 disrupt hantavirus recognition and afford protection against lethal infection[J]. Nat Commun, 2023, 14(1):4454. DOI:10. 1038/s41467-023-40126-y.

[15]Heinemann P, Schmidt-Chanasit J, Günther S. The N terminus of Andes virus L protein suppresses mRNA and protein expression in mammalian cells[J]. J Virol,2013, 87(12):6975-6985. DOI:10. 1128/JVI. 00043-13.

[16]Padula PJ, Sanchez AJ, Edelstein A, et al. Complete nucleotide sequence of the M RNA segment of Andes virus and analysis of the variability of the termini of the virus S, M and L RNA segments[J]. J Gen Virol,2002, 83(Pt 9):2117-2122. DOI:10. 1099/0022-1317-83-9-2117.

[17]Bellomo CM, Alonso DO, Pérez-Sautu U, et al.Andes Virus genome mutations that are likely associated with animal model attenuation and human person-toperson transmission[J]. mSphere, 2023, 8(3):e00018-23. DOI:10. 1128/msphere. 00018-23.

[18]Jeyachandran AV, Irudayam JI, Dubey S, et al.Comparative analysis of molecular pathogenic mechanisms and antiviral development targeting old and new world hantaviruses[J]. bioRxiv, 2023. DOI:10. 1101/2023. 08. 04. 552083. DOI:10. 1101/2023. 08. 04. 552083.

[19]Williams EP, Nandi A, Nam V, et al. Modeling the immune response for pathogenic and nonpathogenic orthohantavirus infections in human lung microvasculature endothelial cells[J]. Viruses, 2023, 15(9):1806. DOI:10. 3390/v15091806.

[20]Chiang CF, Albariňo CG, Lo MK, et al. Small interfering RNA inhibition of Andes virus replication[J].PLoS One, 2014, 9(6):e99764. DOI:10. 1371/journal. pone. 0099764.

[21]Martínez-Valdebenito C, Angulo J, Le Corre N, et al.A single-nucleotide polymorphism of α(V)β?integrin is associated with the Andes Virus infection susceptibility[J]. Viruses, 2019, 11(2):169. DOI:10. 3390/v11020169.

[22]Gorbunova EE, Mackow ER. Binding of the Andes Virus nucleocapsid protein to RhoGDI induces the release and activation of the permeability factor RhoA[J]. J Virol, 2021, 95(17):e00396-21. DOI:10. 1128/JVI. 00396-21.

[23]Keown JR, Carrique L, Nilsson-Payant BE, et al.Structural characterization of the full-length Hantaan virus polymerase[J]. PLoS Pathog, 2024, 20(12):e1012781. DOI:10. 1371/journal. ppat. 1012781.

[24]Mustonen J, Henttonen H, Vaheri A. Hantavirus infections among military forces[J]. Mil Med, 2024,189(3-4):551-555. DOI:10. 1093/milmed/usad261.

[25]王詝，李博琦，李永久，等.鼩鼱科动物携带汉坦病毒科病毒的研究进展[J].病毒学报，2021, 37(5):1252-1259. DOI:10. 13242/j. cnki. bingduxuebao. 003954.

[26]Martínez VP, Di Paola N, Alonso DO, et al.“Superspreaders” and person-to-person transmission of Andes Virus in Argentina[J]. N Engl J Med, 2020, 383(23):2230-2241. DOI:10. 1056/NEJMoa2009040.

[27]Ferrés M, Martínez-Valdebenito C, Angulo J, et al.Mother-to-child transmission of Andes Virus through breast milk, Chile(1)[J]. Emerg Infect Dis, 2020, 26(8):1885-1888. DOI:10. 3201/eid2608. 200204.

[28]Bellomo C, Alonso D, Coelho R, et al. A newborn infected by Andes virus suggests novel routes of hantavirus transmission:a case report[J]. Clin Microbiol Infect, 2020, 26(1):130-131. DOI:10. 1016/j. cmi. 2019. 09. 012.

[29]Ferrés M, Martínez-Valdebenito C, Henriquez C, et al.Viral shedding and viraemia of Andes virus during acute hantavirus infection:a prospective study[J]. Lancet Infect Dis, 2024, 24(7):775-782. DOI:10. 1016/S1473-3099(24)00142-7.

[30]Züst R, Ackermann-G?umann R, Liechti N, et al.Presence and persistence of Andes Virus RNA in human semen[J]. Viruses, 2023, 15(11):2266. DOI:10. 3390/v15112266.

[31]Padula PJ, Edelstein A, Miguel SD, et al. Hantavirus pulmonary syndrome outbreak in Argentina:molecular evidence for person-to-person transmission of Andes virus[J]. Virology, 1998, 241(2):323-330. DOI:10. 1006/viro. 1997. 8976.

[32]Riesle-Sbarbaro SA, Kirchoff N, Hansen-Kant K, et al. Human-to-human transmission of Andes Virus modeled in Syrian hamsters[J]. Emerg Infect Dis,2023, 29(10):2159-2163. DOI:10. 3201/eid2910. 230544.

[33]Kofman A, Eggers P, Kjemtrup A, et al. Notes from the field:contact tracing investigation after first case of Andes Virus in the United States-Delaware, February2018[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(41):1162-1163. DOI:10. 15585/mmwr. mm6741a7.

[34]姜泓，王丽梅，杜虹，等.汉坦病毒感染者血清病毒RNA的临床意义[J].病毒学报，2020, 36(2):322-327. DOI:10. 13242/j. cnki. bingduxuebao. 003628.

[35]Brocato RL, Wu H, Kwilas SA, et al. Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human source[J]. mBio, 2024, 15(10):e01600-24. DOI:10. 1128/mbio. 01600-24.

[36]Marceau J, Safronetz D, Martellaro C, et al. Bivalent VSV vectors mediate rapid and potent protection from Andes Virus challenge in hamsters[J]. Viruses, 2024,16(2):279. DOI:10. 3390/v16020279.

[37]Prescott J, DeBuysscher BL, Brown KS, et al. Longterm single-dose efficacy of a vesicular stomatitis virusbased Andes virus vaccine in Syrian hamsters[J].Viruses, 2014, 6(2):516-523. DOI:10. 3390/v6020516.

[38]Brocato RL, Wahl V, Hammerbeck CD, et al. Innate immune responses elicited by Sin Nombre virus or type I IFN agonists protect hamsters from lethal Andes virus infections[J]. J Gen Virol, 2018. DOI:10. 1099/jgv. 0. 001131. DOI:10. 1099/jgv. 0. 001131.

[39]Paulsen GC, Frenck R, Tomashek KM, et al. Safety and immunogenicity of an Andes Virus DNA vaccine by needle-free injection:a randomized, controlled phase 1study[J]. J Infect Dis, 2024, 229(1):30-38. DOI:10. 1093/infdis/jiad235.

[40]Avi?inien?A, Ku?inskait?-Kodz?I, Petraityt?-Burneikien?R, et al. Characterization of a panel of cross-reactive hantavirus nucleocapsid protein-specific monoclonal antibodies[J]. Viruses, 2023, 15(2):532.DOI:10. 3390/v15020532.

[41]Duehr J, McMahon M, Williamson B, et al.Neutralizing monoclonal antibodies against the gn and the gc of the Andes Virus glycoprotein spike complex protect from virus challenge in a preclinical Hamster Model[J]. mBio, 2020, 11(2):e00028-20. DOI:10. 1128/mBio. 00028-20.

[42]Williamson BN, Prescott J, Garrido JL, et al.Therapeutic efficacy of human monoclonal antibodies against Andes Virus infection in Syrian hamsters[J].Emerg Infect Dis, 2021, 27(10):2707-2710. DOI:10. 3201/eid2710. 210735.